Iron(III) diacetylmonoxime-2-hydrazinopyridine complex: A new prospective antitumor drug

Abstract Because of the side effects and drug resistance of cisplatin, a basic clinically 
approved chemotherapeutic drug, a new attempt is reported to develop a novel antitumor 
drug based on complexation of iron metal ion with organic moiety that may be effective and 
safer. A newly synthesized iron (III) diacetylmonoxime-2-hydrazinopyridine complex was 
tested firstly for its cytotoxicity and superoxide dismutase (SOD)-mimic activity in vitro then 
for its antitumor activity against Ehrlich ascites carcinoma (EAC) and the related ...